A Prospective Randomized Controlled Trial of Dual-Mobility Components in Primary THA

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium
Interventions
DEVICE

Dual mobility cohort

Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.

DEVICE

Conventional cohort

Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell

Trial Locations (1)

60612

Rush University Medical Center, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Zimmer Biomet

INDUSTRY

lead

Rush University Medical Center

OTHER